Professional Documents
Culture Documents
Crohn Disease
Crohn Disease
Summary
Crohn disease (CD) is an inflammatory bowel disease (IBD), the pathogenesis of which is not fully understood. The clinical presentation of CD may be similar
to ulcerative colitis (UC), the other most common IBD. CD mostly affects young adults and adolescents between the ages of 15 and 35. It typically affects the
terminal ileum, but can discontinuously affect the entire gastrointestinal tract and commonly leads to complications such as fistulas, abscesses, and stenosis.
Clinical features include diarrhea, weight loss, and abdominal pain in the right lower quadrant (RLQ), as well as extraintestinal manifestations in the
eyes, joints, or skin. Diagnosis is based on the patient's medical history, physical examination, lab tests, imaging (e.g., MRI), endoscopy, and serological
testing. Acute episodes are treated with corticosteroids; immunosuppressants may be indicated in severe cases. Antibiotics and surgical intervention may be
needed to help treat complications. As Crohn disease is not localized to a specific region of the GI tract, surgical resection is not a curative option (unlike in
UC), and treatment instead focuses on limiting the progression and recurrence of inflammatory episodes.
NOTES
FEEDBACK
Epidemiology
Prevalence: 200 cases per 100,000 population
Incidence: ∼ 6 cases per 100,000 population per year [1]
Sex: ♂ = ♀
Typical age of onset: bimodal distribution with one peak at 15–35 years and another one at 55–70 years [2][3]
Populations with higher prevalence [4]
o Individuals of Northern European descent
o Individuals of Ashkenazi Jewish descent
Epidemiological data refers to the US, unless otherwise specified.
NOTES
FEEDBACK
Etiology
Cause: Immune dysregulation and dysbiosis, which promotes chronic inflammation, the ultimate cause of which is not fully understood.
Risk factors [4]
o Active and passive smoking of tobacco
o Familial aggregation
o Genetic predisposition (e.g., mutation of the NOD2 gene, HLA-B27 association)
Nicotine consumption is the only (known) controllable risk factor for Crohn disease. Therefore, smoking cessation is especially important in patients with CD.
NOTES
FEEDBACK
Crohn disease activity index (CDAI)
Definition: A validated score used to assess disease activity in Crohn disease calculated using the following variables, assessed over the course of one
week:
o Number of liquid or soft stools per day
o Severity of abdominal pain
o General condition
o Presence of the following
Arthritis/arthralgia
Iritis/uveitis
Erythema nodosum, pyoderma gangrenosum, or aphthous ulcers
Anal fissures, fistulas, or abscesses
Other fistulas
Fever
o Use of antidiarrheal drugs
o Abdominal masses
o Hematocrit
o Percentage above or below standard weight
Interpretation
o 0–149: asymptomatic remission
o 150–220: low to moderate activity
o 221–450: moderate to high activity
o 451–1100: high activity, fulminant disease
NOTES
FEEDBACK
Pathophysiology
Inflammation
Inflammation is most likely caused by immune dysregulation.
Dysregulation of IL-23-Th17 signaling → unrestrained Th17 cell function → inflammation → local tissue damage (edema, erosions/ulcers, necrosis)
→ obstruction, fibrotic scarring, stricture, and strangulation of the bowel [5]
There is evidence that mutations in the nucleotide oligomerization binding domain 2 (NOD2) protein are involved in the development of Crohn
disease, but the exact mechanism is not fully understood. [5]
o Loss of function mutations in NOD2 → ↑ susceptibility for bacterial invasion of the intestinal mucosa → unregulated inflammation
o Dysfunctional NOD2 → overactivity of NF-κB signaling pathway → ↑ production of proinflammatory cytokines and
antimicrobial peptides → chronic autoinflammation
Abscess and fistula formation
Intestinal aphthous ulcers → transmural fissures and inflammation of the intestinal walls → adherence of other organs or the skin → penetration
→ microperforation and abscess formation → macroperforation into these structures → fistula formation
NOTES
FEEDBACK
Clinical features
CD typically occurs episodically with a 30%-risk of recurring inflammation over the span of one year. If symptoms persist for six months, the disease is
considered chronic. Without treatment, relapses and complications are to be expected.
Constitutional symptoms [6]
Low-grade fever
Weight loss
Fatigue
Intestinal symptoms [6]
CD most commonly affects the terminal ileum and colon, but involvement of any part of the GI tract (from mouth to anus, except rectum) is possible.
Chronic diarrhea, typically nonbloody
Abdominal pain, typically in the RLQ
Malabsorption (see “Signs of malabsorption” in “Complications” below)
Palpable abdominal mass
in the RLQ
Enterocutaneous perianal fistulas, often associated with abscess formation [7]
Oral aphthae
Perianal fistulas and abscesses are often the first signs of Crohn disease.
Extraintestinal symptoms [8]
Joints: enteropathic arthritis (e.g., sacroiliitis, spondylitis, inflammation of peripheral joints)
Eyes
o Uveitis
o Iritis
o Episcleritis
Liver/bile ducts: cholelithiasis
Urogenital system: urolithiasis (mostly calcium oxalate stones)
Skin
o Erythema nodosum
o Acrodermatitis enteropathica
o Pyoderma gangrenosum
Associated with various conditions (e.g., IBD, rheumatoid arthritis, and trauma)
Manifests with very painful, rapidly-progressive, red spots that can change into purulent pustules or deep ulcerated lesions with
central necrosis
Commonly located at extensor side of the lower limbs
Treated with immunosuppressants (e.g., corticosteroids, cyclosporine A)
o Pyostomatitis vegetans
NOTES
FEEDBACK
Diagnostics
Approach
Diagnosing CD requires the integration of clinical presentation, laboratory tests, and endoscopic, histologic, pathologic and radiologic findings.
1. If a patient presents with symptoms suggestive of CD, conduct blood tests and stool tests (see “Laboratory tests” below) to rule out other possible
causes for bowel inflammation/GI symptoms. [9]
2. Confirm diagnosis with endoscopy and/or radiographic imaging and/or biopsy.
3. Perform contrast radiological studies and/or ultrasonography to assess extent, severity, and complications (e.g., abscesses, fistulas, and stenoses)
Laboratory tests
Blood [9]
Blood work
o Complete blood count may show signs of pernicious anemia
o ↑ Inflammatory markers (↑ CRP, ↑ ESR, ↑ thrombocytes, and ↑ leukocytes)
Serology: routine use to establish diagnosis is not recommended due to low sensitivity
[10]
o ↑ Anti-Saccharomyces cerevisiae antibodies (ASCA)
o pANCA most likely negative
Stool
Stool analysis
o Stool culture to rule out bacterial gastroenteritis
o Microscopy to examine presence of worm larvae or eggs (ova and parasites)
o Identification of bacterial toxins (e.g., toxin of Clostridium difficile)
o Detection of fecal calprotectin and/or fecal lactoferrin
[11][12]
Proteins associated with neutrophils that can be used as a diagnostic tool for inflammatory bowel disease
Direct correlation between detected amount of proteins and severity of intestinal inflammation
Fecal occult blood test (FOBT)
Imaging [13][14]
Plain x-ray abdomen: may show bowel distention or pneumoperitoneum
Upper GI series with barium swallow and small bowel follow-through (enteroclysis):
used to detect fistulas or stenoses, characteristic findings are:
o Procedure
Water-soluble contrast medium is inserted into the small intestine via a nasopharyngeal tube.
Multiple x-rays are taken in a chronological sequence to evaluate each section.
o Findings
String sign: contrast-filled bowel segment that resembles a string on x-ray
Creeping fat: pathognomonic hyperplasia of adipose tissue that results in accumulation of mesenteric fat around the circumference of
the intestine [15]
May cover more than 50% of the inflamed bowel
Correlates with severity of transmural inflammation
Ultrasound findings
o Gastrointestinal wall thickening caused by inflammation and edema
o Possible detection of abscesses/fistulas
MR enterography: noninvasive, highly sensitive and specific imaging technique that involves the visualization of an oral contrast medium on MRI and
is used in the diagnosis of IBD.
o Used to assess the extent and pattern of intestinal inflammation, detect perianal and pelvic disease, and to predict disease activity
o Characteristic findings are an edematous thickening of the intestinal wall and enlarged lymph nodes.
o Can be done as invasive MRI enteroclysis, during which contrast medium is applied via nasoduodenal tube and the small bowel is distended via
an electric infusion pump.
Endoscopy [16]
Endoscopy confirms the diagnosis, assesses the extent of the disease, differentiates CD from other diseases (e.g., ulcerative colitis, peptic ulcers, etc.), and
may also be used as a therapeutic tool (e.g., dilatation of ducts, intestinal loops).
Ileocolonoscopy: endoscopic examination of the rectum, colon, and terminal ileum that allows for direct visualization of the intestinal mucosa and
sampling of tissue
o Procedure: ileocolonoscopy with biopsies at various locations throughout the terminal ileum, colon, and rectum
o Characteristic macroscopic findings
Segmental/discontinuous pattern of involvement
Snail trails: longitudinal ulcerations
Pinpoint lesions: small, aphthous hemorrhagic mucosal defects
Cobblestone sign: inflamed sections followed by deep ulcerations that resemble cobblestones
Erythema and transmural inflammation (all mucosal layers of the intestinal wall are involved)
Fissures, fistulas
Esophagogastroduodenoscopy
o Used to evaluate for involvement of the esophagus, stomach, and duodenum
o Findings include aphthae on mucosa
Video capsule endoscopy [13]
o Used to evaluate small bowel morphology as an adjunctive to regular endoscopy
o Should be performed prior to regular endoscopy in suspected small bowel obstruction
NOTES
FEEDBACK
Pathology
Skip lesions: a pattern of patchy, discontinuous inflammation in the bowel (affected areas interspersed with normal tissue)
Creeping fat
Hypertrophic lymph nodes
Transmural inflammation
o Noncaseating granulomas
[17]
o Giant cells
o Distinct lymphoid aggregates of the lamina propria
NOTES
FEEDBACK
Differential diagnoses
MAXIMIZE TABLETABLE QUIZ
Crohn disease and ulcerative colitis
Greatly increased
Increased
Frequency/type of Bloody diarrhea with mucus
Typically nonbloody, watery diarrhea
defecation Tenesmus
May be bloody in more severe cases
Urgency
Painful defecation, pain located in LLQ
Mostly constant pain in RLQ
Physical Abdominal cramps and tenderness
Palpable abdominal mass
examination Tachycardia
Low-grade fever
Orthostatic hypotension
Skin
o Pyoderma gangrenosum
Crohn disease and ulcerative colitis
o Erythema nodosum
Eyes
o Uveitis
o Episcleritis
Mouth: aphthous stomatitis
Joints
o Peripheral arthritis
o Spondylitis
Typical location: terminal ileum and colon with rectal
Location sparing Colon (exception: backwash ileitis)
May affect the entire GI tract
of inflammation
Cobblestone sign
Friable mucosa
Pinpoint lesions
Typical diagnostic Mucosal ulcerations can be deep or superficial
Snail trails
findings Crypt abscesses
Creeping fat
Loss of haustra (lead pipe sign)
String sign
Transmural inflammation
Noncaseating granulomas Confined to mucosa and submucosa
Giant cells No granulomas
Histology
Lymphoid aggregates
Treatment
Corticosteroids
Thiopurine analogs (azathioprine, 6-mercaptopurine)
5-aminosalicylic acid (e.g., mesalamine)
Anti-p40 antibodies (e.g., ustekinumab)
6-mercaptopurine
Alpha 4 integrase inhibitors (e.g., natalizumab,
Calcineurin
Medication vedolizumab)
inhibitors (e.g., cyclosporine, tacrolimus)
Possibly antibiotics outside of an acute episode
(e.g., ciprofloxacin, metronidazole)
Biologics (e.g., infliximab, adalimumab)
Loperamide
Antidiarrheal agents
Bile acid binders
Symptomatic treatment
Topical corticosteroids Triamcinolone
First-line: oral corticosteroids Prednisone
Azathioprine
Steroid-sparing: thiopurine analogs
Moderate-to-severe 6-Mercaptopurine
disease
Alternatively Ustekinumab (anti-p40 antibody)
o Anti-p40 antibodies Natalizumab, vedolizumab (alpha
o Alpha 4 integrin inhibitors 4 integrin inhibitors)
Severe/fulminant
First-line: IV corticosteroids Methylprednisolone
disease
If necessary: azathioprine (or 6-
mercaptopurine)